Presentation is loading. Please wait.

Presentation is loading. Please wait.

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

Published byMonica María Godoy Rojas Modified over 5 years ago

Similar presentations

Presentation on theme: "The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined."— Presentation transcript:

1 The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined according to severity. The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined according to severity. In a) the severe group it was 85% in the NBS versus 64% in the symptoms group (p=0.007); in b) the moderate group it was 94% in the NBS versus 86% in the symptoms group (p=0.016); and in c) the mild group it was 98% in the NBS versus 93% in the symptoms group (p=0.6). Survival probability is presented on a scale from 0.5 to 1.0 for readability. HR: hazard ratio; OS: overall survival. Gloria Tridello et al. ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined."

Similar presentations

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.
Echocardiography view

Echocardiography view
Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.

Bland–Altman plot of projected apnoea threshold of measurement 1 versus 2. a) Rebreathing (R) method (n=20); b) steady-state (SS) method (n=18). Bland–Altman.
Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.

Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
Composition of microbial communities in induced sputa of healthy and mild, moderate, severe or very severe (end-stage) lung disease affected individuals.

Composition of microbial communities in induced sputa of healthy and mild, moderate, severe or very severe (end-stage) lung disease affected individuals.
A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Survival without tracheostomy

Survival without tracheostomy
Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.

Symptoms measured by Edmonton Symptom Assessment Scale according to modified Medical Research Council (mMRC) dyspnoea scale groups. Symptoms measured by.
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.
Results from a recent bench test of 13 noninvasive ventilators using a computer-controlled active patient simulator. a) Proportion of the preset tidal.

Results from a recent bench test of 13 noninvasive ventilators using a computer-controlled active patient simulator. a) Proportion of the preset tidal.

Similar presentations

Ads by Google